In 2023, Johnson & Johnson announced it had stopped research and development on therapeutics for many infectious diseases, including hepatitis and tuberculosis. Less visibly, AbbVie shuttered last year its pro bono technical R&D support on infectious diseases such as malaria and Chagas’ disease. These are not isolated cases. An increasing number of large pharmaceutical companies…
Betel Quid Use Linked to Higher Risk of COPD Deaths, Study Finds We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
WHO Expands 2025 Essential Medicines List, Adding Life-Saving Cancer and Diabetes Treatments We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link